Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: Acute effects of continuous octreotide infusion

European Journal of Endocrinology

Volumn 142, Issue 2, 2000, Pages 179-186

  Del Rio, G ^a   Velardo, A ^b   Mascadri, C ^b   Zalteri, G ^b   Papi, G ^b   Menozzi, R ^b   Giustina, A ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; GROWTH HORMONE; NORADRENALIN; OCTREOTIDE; PLACEBO;

ACROMEGALY; ADENOHYPOPHYSIS DISEASE; ADRENERGIC SYSTEM; ADULT; ARTICLE; BODY POSITION; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HEART HYPERTROPHY; HUMAN; MALE; PRIORITY JOURNAL;

ACROMEGALY; ADULT; BLOOD PRESSURE; COLD; DIASTOLE; EPINEPHRINE; FEMALE; HAND; HORMONES; HUMANS; IMMERSION; INFUSION PUMPS; MALE; MIDDLE AGED; NOREPINEPHRINE; OCTREOTIDE; POSTURE; REFERENCE VALUES; SYSTOLE; TIME FACTORS;

EID: 0034090236     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lim MJ, Barkan AL & Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Annals of Internal Medicine 1992 117 719-726.
2. Melmed S, Acromegaly. New England Journal of Medicine 1990 322 966-977.
3. Giustina A, Boni E, Romanelli G, Grassi V & Giustina G. Cardiopulmonary performance during exercise in acromegaly and the effects of acute suppression of growth hormone hypersecretion with octreotide. American Journal of Cardiology 1995 75 1042-1047.
4. Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. Journal of Endocrinological Investigation 1991 14 17-23.
5. Thuesen L, Christensen SM, Weeke J, Orskov H & Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clinical Endocrinology 1989 30 619-625.
6. Bertoni PD & Morandi G. Impaired left ventricular diastolic function in acromegaly: an echocardiographic study. Acta Cardiologica 1986 42 1-9.
7. Fazio S, Cittadini A, Cuocolo B, Merola B, Sabatini D & Colao A et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. Journal of Clinical Endocrinology and Metabolism 1994 79 441-446.
8. Liebermann SA & Hoffman AR. Sequelae to acromegaly: reversibility with treatment of the primary disease. Hormone and Metabolic Research 1990 22 313-318.
9. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine 1990 113 921-925.
10. Hauger-Klevene JH, Barontoni De G, Moyano MB & Nabia G. Plasma renin activity and catecholamines in acromegaly. Clinical Research 1972 20 865.
11. Marek J, Horky K, Kopecka J, Mestan J & Sramkova J. Catecholamine excretion in acromegalics. Endokrinologie 1974 63 304-311.
12. Cryer PE. Plasma norepinephrine and epinephrine in acromegaly. Journal of Clinical Endocrinology and Metabolism 1975 41 542-545.
13. Rozemberg I, Manchon P, Sabatier C, Hazard J & Lhoste F. Effects of thyrotrophin-releasing hormone on plasma catecholamine levels in acromegalics. Acta Endocrinologica 1985 109 19-24.
14. Van Loon GR. Abnormal plasma catecholamine responses in acromegalics. Journal of Clinical Endocrinology and Metabolism 1979 48 784-789.
15. Sechen SJ, Dunshea FR & Bauman DE. Somatotropin in lactating cows: effect on response to epinephrine and insulin. American Journal of Physiology 1990 258 E582-E588.
16. Beauville M, Harant I, Riviere D, Tauber MT, Tauber JP & Garrigues M. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. American Journal of Physiology 1992 263 E467-E472.
17. Watt PW, Finley E, Cork S, Clegg RA & Vernon RG. Chronic control of the beta and alfa2-adrenergic systems of sheep adipose tissue by growth hormone and insulin. Biochemical Journal 1991 273 39-42.
18. Peters JP. Consequences of accelerated gain and growth hormone administration for lipid metabolism in growing beef steers. Journal of Nutrition 1986 116 2490-2503.
19. James RA, White MC, Chatterjee S, Marciaj H & Kendal-Taylor P. A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly. European Journal of Clinical Investigation 1992 22 554-561.
20. Sahn B, De Maria A, Kisslo J & Weyman A. The committee on M-mode standardization of echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978 58 1072-1083.
21. Feigenbaum H. Echocardiography, edn 4, pp 621-639. Philadelphia: Lea and Febiger, 1986.
22. Devereux RB & Reichek N. Echocardiographic determination of left ventricular mass in men - anatomical validation of the method. Circulation 1977 55 613-618.
23. Wilson J. Non-invasive assessment of load reduction in patients with asymptomatic aortic regurgitation. American Journal of Medicine 1980 68 664-668.
24. Del Rio G, Velardo A, Zizzo G, Marrama P & Della Casa L. Sex differences in catecholamine response to clonidine. International Journal of Obesity 1993 17 465-469.
25. Del Rio G, Carani C, Velardo A, Procopio M, Zizzo G, Savio P et al. The effects of clonidine on blood pressure. catecholamine and GH release in hypogonadal men is preserved and not influenced by testosterone replacement therapy, Journal of Endocrinology Investigations 1996 19 505-510.
26. Dimsdale JF & Ziegler MJ. What do plasma and urinary measures of catecholamines tell us about human response to stressors? Circulation 1991 83 Suppl 2 36-42.
27. Muller EE & Nisticò G. Neurotransmitter regulation of the anterior pituitary. In Brain Messengers and the Pituitary, pp 404-537. Eds EE Muller & G Nisticò, San Diego: Academic Press, 1989.
28. Wolthers T, Grofte T, Norelund H, Poulsen PL, Andreasen F, Christiansen JS et al. Differential effects of growth hormone and prednisolone on energy metabolism and leptin levels in humans. Metabolism 1998 47 83-88.
29. Bisi G, Podio V, Valletto MR, Broglio F, Bertuccio G, Del Rio G et al. Radionuclide angiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. European Journal of Endocrinology 1999 140 322-327.
30. Sverrisdottir YB, Elam M, Herlitz H, Bengtsson BA & Johannsson G. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 1881-1885.
31. Saccá L, Cittadini A & Fazio S. Growth hormone and the heart. Endocrine Reviews 1994 15 555-573.
32. Volterranni M, Desenzani P, Lorusso R, D'Aloia A, Manelli F & Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. The Lancet 1997 349 1067-1068.
33. Giustina A, Volterrani M, Manelli F, Desenzani P, Poiesi C, Lorusso R et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. American Heart Journal 1999 137 1035-1043.
34. Robertson D, Johnson GA, Robertson RM, Nies AS, Shand DG, Oates JA et al. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 1979 59 637-643.
35. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995 92 3206-3210.
36. Maynard KI, Saville VL & Burnstock G. Somatostatin modulates vascular sympathetic neurotransmission in the rabbit ear artery. European Journal of Pharmacology 1991 196 125-131.
37. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ et al. Treatment with a somatostatin analog decreases pancreatic B-cell sensitivity to glucose. Journal of Clinical Endocrinology and Metabolism 1990 71 994-1002.
38. Krentz AJ, Boyle PJ, Macdonald LM & Schade DS. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994 43 24-31.
39. Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HPH, Parmer RJ et al. Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. Journal of Clinical Endocrinology and Metabolism 1991 72 616-622.
40. Reisine T & Bell GI. Molecular biology of somatostatin receptors. Endocrine Review 1995 16 427-442.
41. Manelli F, Desenzani P & Damiani P. Time-course of the cardiovascular response to exercise following a single slow release lanreotide injection in patients with active acromegaly. Journal of Endocrinological Investigation 1997 20 92 (Abstract 37P).